ArticleBMJ global health2025
Global medium-term research priority setting for seasonal malaria chemoprevention: results from an eDelphi study.
Article in BMJ global health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
introductionSeasonal malaria chemoprevention (SMC) with sulfadoxine-pyrimethamine and amodiaquine (SPAQ) has been delivered in sub-Saharan Africa since 2014, reaching over 40 million children in 2022. New questions are emerging related to SMC's sustainability, integration with other interventions and introduction to new regions. Meanwhile, new WHO malaria guidelines have substantially increased flexibility for tailoring malaria strategies to local contexts. The SMC Alliance, bringing together researchers and implementers, commissioned a consultation to identify medium-term SMC research priorities.
methodsThe consultation was conducted online from September 2022 to September 2023 using the eDelphi methodology. An initial list of 46 research priorities was compiled during a workshop with SMC implementers. The wider expert consultation comprised three waves of online surveys available in English, French and Portuguese. Respondents rated research priorities on their importance, feasibility and degree to which they had already been addressed; responses determined elimination or retention of research priorities after each survey wave. Respondents suggested their own research priorities for rating. We also collected anonymised data on respondents' characteristics. A final ranking exercise was conducted to reach consensus on a top 10 list of research priorities.
resultsA total of 67 unique respondents residing in 20 countries provided 96 survey responses. The surveys achieved balanced representation of respondents by gender, country of residence and professional background. Of the 25 research priorities retained for ranking, the highest-ranked included 'evaluate duration of prophylactic protection offered by SPAQ and other SMC medicines' and 'evaluate the effect of integrating SMC with other malaria prevention interventions on development of antimalarial resistance'.
conclusionsResearch priorities related to sustainability, antimalarial resistance, integration with other interventions and improving quality of SMC delivery featured prominently among the highest-ranked research priorities. It is hoped the results of this consultation can encourage research uptake, guide new research and inform programme adaptation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.